直至2018年之后,随着仑伐替尼和免疫治疗的出现,多项研究显示仑伐替尼、靶免联合、双免疫等方案一线治疗具有更优疗效,为HCC一线治疗带来崭新格局,为晚期HCC患者增添了一线治疗新选择。 Q2:如您所述,仑伐替尼及免疫为基础的联合治疗方案为...
Results from the phase 3 CARES-310 trial (NCT03764293), published in The Lancet, showed that at a median follow-up of 14.5 months (IQR, 9.1-18.7), the median OS was extended with the combination (n = 272) vs sorafenib (n = 271) at 22.1 months (95% CI, 19.1-27.2) vs ...
5A-B). Together, these results indicate that AFP exerts its growth-promoting effect on HCC cells by suppressing the Fas-mediated extrinsic apoptotic pathway. In mouse liver tumor samples, we observed that high levels of AFP were usually accompanied by downregulated Fas expression (Fig. 4c and ...
The results of the cell cycle analysis (Fig.7D) showed no significant difference in the G2/M phase cell proportion of HepG2.2.15 cells between the Control group and the CC@PP group. However, a significant increase in the G2/M phase cell proportion was observed in the CC@AC&SF@PP grou...
While this original study relied on explant pathology for determination of tumor size and number, they corroborated these results in a small number of patients (n = 45) using imaging findings. The UCSF criteria were subsequently validated internally by the same group in 2007 [8], and by the ...
公司公告2023年中报。2023H1,公司实现总收入52.98亿元(+10.84%),归母净利润2.37亿元(+25.14%),扣非归母净利润2.30亿元(+60.83%)。23Q2单季,公司实现总收入27.77亿元(+12.72%),归母净利润1.76亿元(+20.54%),扣非归母净利润1.55亿元(+43.20%)。
应答报名 4.1 应答报名时间: 2023 年 04 月 28 日 16 时起至 2023 年 05 月 06 日 16 时止(北 京时间,下同). 4.1 报名方式:网络报名. 潜在应答人须登录中国核工业集团有限公司采购管理信息系统 (https://w...
红星资本局8月22日消息,今日快手(01024.HK)发布2023年第二季度及中期业绩。 财报显示,本季度快手总营收同比增长27.9%至277.4亿元。上市后,首次录得集团层面国际会计准则(IFRS)净利润为正值,达14.8亿元,经调整净利润为26.9亿元。二季度,快手应用的用户规模持续增长,平均日活跃用户同比增长8.3%达3.76亿,平均月活跃用户...